Lung cancer key for Takeda's alisertib after Ph III lymphoma flop

Takeda's hopes for its first-in-class Aurora kinase inhibitor now rest on Phase II studies in lung cancer after the company pulled the plug on its Phase III trial in a rare form of lymphoma.